menu
    • menu
    [{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"10","companyTruncated":"Castle Creek Biosciences \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Castle Creek Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"U.S. Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ U.S. Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Castle Creek Biosciences \/ U.S. Food & Drug Administration"}]

    Find Clinical Drug Pipeline Developments & Deals for Dabocemagene Autoficel

    Menu

    Dabocemagene Autoficel

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Castle Creek Biosciences

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            Castle Creek Biosciences

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dabocemagene Autoficel

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : U.S. Food & Drug Administration

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3...

                            Details : The grant supports a meaningful portion of the Phase 3 clinical development of dabocemagene autoficel (FCX-007, D-Fi), an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

                            Brand Name : FCX-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 21, 2021

                            Lead Product(s) : Dabocemagene Autoficel

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : U.S. Food & Drug Administration

                            Deal Size : $1.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Castle Creek Biosciences

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            Castle Creek Biosciences

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dabocemagene Autoficel

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of Debcoemagene Aut...

                            Details : first patient has been dosed in the DeFi-RDEB Phase 3 clinical trial evaluating debcoemagene autoficel (D-Fi), the company’s lead gene therapy candidate formerly designated FCX-007, in recessive dystrophic epidermolysis bullosa (RDEB).

                            Brand Name : FCX-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 28, 2020

                            Lead Product(s) : Dabocemagene Autoficel

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Castle Creek Biosciences

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            Castle Creek Biosciences

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dabocemagene Autoficel

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Fidelity Management & Research Company

                            Deal Size : $55.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Castle Creek Biosciences Announces $75 Million Investment

                            Details : The company plans to use the funding to advance and expand its gene therapy pipeline, led by the Phase 3 clinical development of FCX-007.

                            Brand Name : FCX-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 25, 2020

                            Lead Product(s) : Dabocemagene Autoficel

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Fidelity Management & Research Company

                            Deal Size : $55.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth